MK-2866 (Ostarine)
Shop MK-2866 (Ostarine) on KimeraChems · code GUIDE (10% off)Definition
Ostarine, also known as MK-2866, is a selective androgen receptor modulator (SARM) originally developed to investigate treatment for muscle wasting conditions and bone health support without the androgenic effects associated with traditional anabolic steroids. It selectively binds androgen receptors in muscle and bone tissue, promoting anabolic activity in those tissues while largely sparing androgenic effects elsewhere. Among SARMs, Ostarine is widely regarded as one of the milder and more well-tolerated options in the category, making it a common entry point in SARM research designs and a relevant variable in studies involving female models at lower exposure levels. It is also one of the few compounds in this category consistently associated with mood and joint health signals rather than the aggression or connective tissue stress observed with more androgenic compounds.
Available Formats
- 30 mL liquid solution
- Dry fill capsules
- Tablets
- 10 mL aliquot vial (advanced carrier blend)
- 1 gram powder
Mechanism of Action
- Selective androgen receptor binding in muscle and bone tissue, activating anabolic gene expression and protein synthesis pathways while minimizing androgenic signaling in tissues like the prostate and skin.
- Muscle protein synthesis upregulation through AR-mediated transcriptional activity, with lean muscle maintenance and preservation signals particularly noted in caloric deficit and recomposition model contexts.
- Bone remodeling support via androgen receptor activity in skeletal tissue, contributing to improved bone mineral density and structural integrity signals consistent with its original medical research context.
- Mild HPG axis suppression producing a less pronounced endogenous testosterone reduction compared to more potent SARMs, though still sufficient to warrant consideration of endocrine recovery protocols in longer exposure research designs.
- Joint tissue support with Ostarine's effects on connective tissue and synovial fluid signaling commonly cited as contributing to joint comfort observations in research contexts.
Safety Profile
- Testosterone suppression milder than most SARMs but still present in research models, with endocrine recovery protocol design remaining a relevant consideration after extended exposure windows.
- Mild androgenic signals including possible acne or libido changes observed in some model contexts, though significantly less pronounced than with traditional androgens or more potent SARMs.
- Cardiovascular and lipid profile shifts including potential cholesterol marker changes warranting monitoring as a standard variable, particularly in longer or higher dose research designs.
- Liver and kidney stress reported at higher exposure levels, making biomarker monitoring throughout the research window a standard safeguard rather than an optional consideration.
For educational purposes only. Not for human consumption.